Targeted Oncolytic Therapy for Hepatocellular Carcinoma with High Specificity and Efficiency

Ziheng Zhan

doi:10.54097/m1rfb241

Authors

Ziheng Zhan

DOI:

https://doi.org/10.54097/m1rfb241

Keywords:

Hepatocellular Carcinoma, Oncolytic Virus, AFP, therapy resistance and GPX4.

Abstract

Introduction and hypothesis: Hepatocellular Carcinoma (HCC) represents a significant global health burden, characterized by high mortality rates and limited therapeutic options. Annually, over 500,000 new cases of HCC are diagnosed globally, with the overall five-year survival rate for advanced stages ranging from a mere 5-9%. This study proposes a novel oncolytic virus (OV) approach for HCC treatment, hypothesizing that a combination of alpha-fetoprotein (AFP) promoter/enhancer system for precise targeting of HCC cells while sparing normal liver tissue, Diphtheria Toxin A (DTA) for potent cell lysis, and shGPX4 to overcome treatment resistance through ferroptosis pathway. Methodology: An Adeno-Associated Virus 2 (AAV2) vector was engineered to contain an AFP promoter/enhancer-driven DTA gene and a short hairpin RNA targeting GPX4 (shGPX4). The virus was produced in HEK293T cells, purified, and its efficacy was tested on different HCC cell lines (HepG2, Hep3B and Huh7) and normal hepatocyte cell line (MIHA) at various multiplicities of infection (MOIs). Cell viability was assessed using CCK8 assays. Moreover, constructed AAV2’s function on anti-resistance is tested on combination treatment with different-dosage Cisplatin. Results: The AFP promoter/enhancer was specifically selected based on comprehensive analysis of published dataset, which demonstrated significantly high AFP expression in liver cancer, correlation with disease outcomes, survival outcomes and specific epigenetic regulation in HCC. Further in vitro experiments demonstrated the construct AAV2 oncolytic virus has remarkable specificity and therapeutic efficacy. Multiple analysis revealed significant cytotoxicity in high-AFP-expressing HCC cell lines (HepG2 and Hep3B), reducing cell viability to approximately 40% at maximum MOI, while showing minimal impact on normal hepatocytes (MIHA). Moreover, combination therapy studies with cisplatin showed significant synergistic effects, particularly in chemoresistant cells, attributed to the GPX4 suppression mechanism. Conclusion: Our novel OV construct shows promising results in selectively targeting and eliminating HCC cells while sparing normal liver tissue. This approach addresses the critical needs for specificity and overcoming treatment resistance in HCC therapy. Further in vivo studies are warranted to fully elucidate its efficacy and safety, potentially leading to more effective and targeted treatments for hepatocellular carcinoma.

Downloads

Download data is not yet available.

References

[1] Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., and Finn, R.S. (2021). Hepatocellular carcinoma. Nat Rev Dis Primers 7, 6. 10.1038/s41572-020-00240-3.

[2] Li, X., Sun, X., Wang, B., Li, Y., and Tong, J. (2023). Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci 18, 100771. 10.1016/j.ajps.2022.100771.

[3] Singh, A.K., Kumar, R., and Pandey, A.K. (2018). Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers. Curr Chem Genom Transl Med 12, 9-26. 10.2174/2213988501812010009.

[4] Forner, A., Reig, M., and Bruix, J. (2018). Hepatocellular carcinoma. Lancet 391, 1301-1314. 10.1016/S0140-6736(18)30010-2.

[5] Pinter, M., and Peck-Radosavljevic, M. (2018). Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 48, 598-609. 10.1111/apt.14913.

[6] Vogel, A., and Saborowski, A. (2020). Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev 82, 101946. 10.1016/j.ctrv.2019.101946.

[7] Hassanipour, S., Vali, M., Gaffari-Fam, S., Nikbakht, H.A., Abdzadeh, E., Joukar, F., Pourshams, A., Shafaghi, A., Malakoutikhah, M., Arab-Zozani, M., et al. (2020). The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 19, 108-130. 10.17179/excli2019-1842.

[8] Cai, J., Lin, K., Cai, W., Lin, Y., Liu, X., Guo, L., Zhang, J., Xu, W., Lin, Z., Wong, C.W., et al. (2020). Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Mol Oncol 14, 3153-3168. 10.1002/1878-0261.12820.

[9] Kaufman, H.L., Kohlhapp, F.J., and Zloza, A. (2016). Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 15, 660. 10.1038/nrd.2016.178.

[10] Fionda, C., Stabile, H., Cerboni, C., Soriani, A., Gismondi, A., Cippitelli, M., and Santoni, A. (2020). Hitting More Birds with a Stone: Impact of TGF-beta on ILC Activity in Cancer. J Clin Med 9. 10.3390/jcm9010143.

[11] Bommareddy, P.K., Patel, A., Hossain, S., and Kaufman, H.L. (2017). Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol 18, 1-15. 10.1007/s40257-016-0238-9.

[12] Raman, S.S., Hecht, J.R., and Chan, E. (2019). Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy 11, 705-723. 10.2217/imt-2019-0033.

[13] Tijtgat, J., De Munck, J., Dufait, I., Schwarze, J.K., Van Riet, I., Franceschini, L., Breckpot, K., Aerts, J.L., Neyns, B., and Tuyaerts, S. (2021). Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Front Immunol 12, 733506. 10.3389/fimmu.2021.733506.

[14] Kaufman, H.L., Shalhout, S.Z., and Iodice, G. (2022). Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Front Mol Biosci 9, 834841. 10.3389/fmolb.2022.834841.

[15] Bijlani, S., Pang, K.M., Sivanandam, V., Singh, A., and Chatterjee, S. (2021). The Role of Recombinant AAV in Precise Genome Editing. Front Genome Ed 3, 799722. 10.3389/fgeed.2021.799722.

[16] Zaiss, A.K., and Muruve, D.A. (2005). Immune responses to adeno-associated virus vectors. Curr Gene Ther 5, 323-331. 10.2174/1566523054065039.

[17] Xu, Z., Zhang, Y., Dai, H., and Han, B. (2022). Epithelial-Mesenchymal Transition-Mediated Tumor Therapeutic Resistance. Molecules 27. 10.3390/molecules27154750.

[18] Liao, H., Shi, J., Wen, K., Lin, J., Liu, Q., Shi, B., Yan, Y., and Xiao, Z. (2021). Molecular Targets of Ferroptosis in Hepatocellular Carcinoma. J Hepatocell Carcinoma 8, 985-996. 10.2147/JHC.S325593.

[19] Tsuchiya, N., Sawada, Y., Endo, I., Saito, K., Uemura, Y., and Nakatsura, T. (2015). Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol 21, 10573-10583. 10.3748/wjg.v21.i37.10573.

[20] Mateyak, M.K., and Kinzy, T.G. (2013). ADP-ribosylation of translation elongation factor 2 by diphtheria toxin in yeast inhibits translation and cell separation. J Biol Chem 288, 24647-24655. 10.1074/jbc.M113.488783.

[21] Kwon, O.J., Kim, P.H., Huyn, S., Wu, L., Kim, M., and Yun, C.O. (2010). A hypoxia- and alpha-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16, 6071-6082. 10.1158/1078-0432.CCR-10-0664.

[22] Kim, J., Lee, B., Kim, J.S., Yun, C.O., Kim, J.H., Lee, Y.J., Joo, C.H., and Lee, H. (2002). Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 180, 23-32. 10.1016/s0304-3835(02)00017-4.

[23] Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365, 1673-1683. 10.1056/NEJMoa1106152.

[24] Hangauer, M.J., Viswanathan, V.S., Ryan, M.J., Bole, D., Eaton, J.K., Matov, A., Galeas, J., Dhruv, H.D., Berens, M.E., Schreiber, S.L., et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247-250. 10.1038/nature24297.

[25] Nagalo, B.M., Zhou, Y., Loeuillard, E.J., Dumbauld, C., Barro, O., Elliott, N.M., Baker, A.T., Arora, M., Bogenberger, J.M., Meurice, N., et al. (2023). Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. Hepatology 77, 1943-1957. 10.1002/hep.32769.